Format

Send to

Choose Destination
Cancer Med. 2019 Jun;8(6):2942-2949. doi: 10.1002/cam4.2201. Epub 2019 May 2.

Prognostic factors for overall survival in patients with chronic myeloid leukemia treated with imatinib at the National Cancer Institute - Mexico, from 2000 to 2016.

Author information

1
Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología - Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.
2
Support and Research Promotion Program (AFINES), Faculty of Mefdicine, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.
3
Department of Hematology, National Cancer Institute, Mexico City, Mexico.
4
Department of Hematology, Instituto Nacional de Cardiología "Ignacio Chávez", Mexico City, Mexico.
5
Smell and Taste Center, Department of Otorhinolaryngology: Head and Neck Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
6
Mediciencias Research Group, Unicolciencias/Universidad Nacional, Bogota, Colombia.
7
Departmento de Informática Biomédica, Faculty of Medicine, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.

Abstract

To determine potential predictors of long-term survival in a large set of Hispanic (Mexican) patients with chronic myeloid leukemia (CML) treated with imatinib. We conducted an analysis with data from 411 patients with CML treated at the National Cancer Institute - Mexico, between January 2000 and December 2016. We found a median age at diagnosis of 40 years (range: 18-84 years). The survival rate at 150 months was 82.02%, and we found that phase at diagnosis (β: 0.447, 95% Confidence Interval [95% CI]: 0.088, 0.806; P = 0.015), prognostic scales (Sokal [P = 0.021] and Hasford [β: 0.369, 95% CI: 0.049, 0.688; P = 0.024]) and hematological response at 3 months (β: 0.717, 95% CI: 0.443, 0.991; P < 0.001), but not molecular response (P = 0.834 for 6 months, P = 0.927 for 12 months, P = 0.250 for 18 months), were independently associated with overall survival. Survival analysis in subsets, according to the initial phase (chronic, accelerated and blastic phase) did not show any effect according to prognostic scales (P > 0.05). Mexican patients with CML have repeatedly been diagnosed at earlier ages. Prognostic factors in CML may differ according to the ethnic or geographical context. We found that phase at diagnosis, prognostic scale and hematological response at 3 months were independent predictors of survival.

KEYWORDS:

chronic myeloid leukemia; hispanic; overall survival; prognostic factors

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center